Alexander Spira, MD, PhD, FACP

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Amgen
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Mirati Therapeutics
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gritstone Oncology
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Jazz Pharmaceuticals
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Takeda
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen Research & Development
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Mersana
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gritstone Bio
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Daiichi Sankyo/Astra Zeneca
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Regeneron
    Date added:
    08/16/2023
    Date updated:
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond